72 related articles for article (PubMed ID: 30342909)
1. Frequencies of PD-1- and PD-L1- positive T CD3
Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
[TBL] [Abstract][Full Text] [Related]
2. The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.
Grywalska E; Smarz-Widelska I; Krasowska-Zajac E; Korona-Glowniak I; Zaluska-Patel K; Mielnik M; Podgajna M; Malm A; Rolinski J; Zaluska W
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):133-143. PubMed ID: 28770269
[TBL] [Abstract][Full Text] [Related]
3. CD4
Piersiala K; Farrajota Neves da Silva P; Hjalmarsson E; Kolev A; Kågedal Å; Starkhammar M; Elliot A; Marklund L; Margolin G; Munck-Wikland E; Kumlien Georén S; Cardell LO
Cancer Sci; 2021 Mar; 112(3):1048-1059. PubMed ID: 33462898
[TBL] [Abstract][Full Text] [Related]
4. [The proportion of CD19
Xie Z; Dai L; He H; Hong D; Wang Y; Xu W; Chen Z; Li B; Xie C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Feb; 40(2):148-157. PubMed ID: 38284256
[TBL] [Abstract][Full Text] [Related]
5. Percentages of PD-1
Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.
Horwitz DA; Pan S; Ou JN; Wang J; Chen M; Gray JD; Zheng SG
Clin Immunol; 2013 Dec; 149(3):450-63. PubMed ID: 24211847
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.
Dowlatshahi M; Huang V; Gehad AE; Jiang Y; Calarese A; Teague JE; Dorosario AA; Cheng J; Nghiem P; Schanbacher CF; Thakuria M; Schmults CD; Wang LC; Clark RA
J Invest Dermatol; 2013 Jul; 133(7):1879-89. PubMed ID: 23419694
[TBL] [Abstract][Full Text] [Related]
8. CD4
Kang S; Jin S; Mao X; He B; Wu C
J Immunol Res; 2024; 2024():5582151. PubMed ID: 38690552
[TBL] [Abstract][Full Text] [Related]
9. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
Malaspina TS; Gasparoto TH; Costa MR; de Melo EF; Ikoma MR; Damante JH; Cavassani KA; Garlet GP; da Silva JS; Campanelli AP
Cancer Immunol Immunother; 2011 Jul; 60(7):965-74. PubMed ID: 21442435
[TBL] [Abstract][Full Text] [Related]
10. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
[TBL] [Abstract][Full Text] [Related]
11. Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma.
Xiong Y; Neskey DM; Horton JD; Paulos CM; Knochelmann HM; Armeson KE; Young MRI
BMC Cancer; 2020 Mar; 20(1):229. PubMed ID: 32183719
[TBL] [Abstract][Full Text] [Related]
12. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract][Full Text] [Related]
13. A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.
Holcomb EA; Zou W
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104808
[TBL] [Abstract][Full Text] [Related]
14. Increased liver temperature efficiently augments human cellular immune response: T-cell activation and possible monocyte translocation.
Kida Y; Tsuji-Kawahara S; Ostapenko V; Kinoshita S; Kajiwara E; Kawabata H; Yuasa T; Nishide I; Yukawa S; Ichinose M; Miyazawa M
Cancer Immunol Immunother; 2006 Dec; 55(12):1459-69. PubMed ID: 16491400
[TBL] [Abstract][Full Text] [Related]
15. Is CD69 an effective brake to control inflammatory diseases?
González-Amaro R; Cortés JR; Sánchez-Madrid F; Martín P
Trends Mol Med; 2013 Oct; 19(10):625-32. PubMed ID: 23954168
[TBL] [Abstract][Full Text] [Related]
16. Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes.
Lombardi A; Trombetta E; Cattaneo A; Castelli V; Palomba E; Tirone M; Mangioni D; Lamorte G; Manunta M; Prati D; Ceriotti F; Gualtierotti R; Costantino G; Aliberti S; Scaravilli V; Grasselli G; Gori A; Porretti L; Bandera A
Front Immunol; 2020; 11():560330. PubMed ID: 33362757
[TBL] [Abstract][Full Text] [Related]
17. New Predictor of Organ Failure in Acute Pancreatitis: CD4+ T Lymphocytes and CD19+ B Lymphocytes.
Shi C; Hou C; Zhu X; Peng Y; Guo F; Zhang K; Huang D; Li Q; Miao Y
Biomed Res Int; 2018; 2018():1012584. PubMed ID: 30627533
[TBL] [Abstract][Full Text] [Related]
18. Increased proportions of circulating PD-1
Miedema JR; de Jong LJ; Kahlmann V; Bergen IM; Broos CE; Wijsenbeek MS; Hendriks RW; Corneth OBJ
Respir Res; 2024 May; 25(1):196. PubMed ID: 38715030
[TBL] [Abstract][Full Text] [Related]
19. PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration.
Zieliński M; Sakowska J; Iwaszkiewicz-Grześ D; Gliwiński M; Hennig M; Żalińska M; Wołoszyn-Durkiewicz A; Jaźwińska-Curyłło A; Kamińska H; Owczuk R; Młynarski W; Jarosz-Chobot P; Bossowski A; Szadkowska A; Fendler W; Beń-Skowronek I; Chobot A; Myśliwiec M; Siebert J; Marek-Trzonkowska N; Trzonkowski P
Int Immunopharmacol; 2024 May; 132():111919. PubMed ID: 38554443
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and LAG-3 positive T cells are related with the prognosis of patients with chronic kidney disease.
Jiang H; Wu J; Zhang J
Exp Cell Res; 2024 May; 438(1):114027. PubMed ID: 38574959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
